Kiniksa Pharmaceuticals International, plc (KNSA) Form 10-Q — Oct 27, 2026
Kiniksa reported Q3 2026 ARCALYST net product revenue of $286.0 million, up 58% from $180.9 million a year earlier, driven primarily by an increase in patients on therapy. Net income more than doubled to $47.3 million ($0.56 diluted EPS) from $18.4 million in Q3 2025, and nine-month net income reached $95.4 million with $144.9 million in operating cash flow. The company ended the quarter with $81.7 million in cash and $487.1 million in short-term investments, and said its cash is sufficient to fund operations for at least the next 12 months.
Key figures
- Eps
- diluted $0.56 (Q3 2026); basic $0.61; nine-month diluted $1.14
- Revenue
- 285970000
- Guidance
- PASTORALE Phase 3 data for KPL-387 expected in H2 2027; commercialization expected 2028-2029; Phase 1 of KPL-1161 expected to initiate by end of 2026
- Net Income
- 47345000
- Revenue Yoy
- +58% (Q3 2026 vs Q3 2025); nine-month revenue $743.8M vs $475.4M (+56%)
- Total Assets
- 983243000
- Cash Position
- $81.66M cash and equivalents plus $487.1M short-term investments (~$568.8M total liquidity)
- Q3 2025 revenue
- 180855000
- Q3 2025 net income
- 18435000
- Q3 2026 net income
- 47345000
- Nine month net income
- 95369000
- Operating cash flow 9m
- 144941000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.